Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RT01-89Zr PET Imaging in Solid Tumors
NCT07505069Phase 1Recruiting
- Sponsor
- Nanolattix
- Start
- Jan 2026
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RT01 in solid tumor, sponsored by Nanolattix. Primary endpoint: Safety evaluation at 21 days. Started Jan 2026; status: recruiting.
02
Drugs
RT01
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07505069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505069.